ReviewACS pharmacology & translational science2020
IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies.
Review in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- The IL-33/ST2 pathway to modulate the inflammatory microenvironment: A new therapeutic target in chronic obstructive pulmonary disease.Biochemistry and biophysics reports · 2026Review
- Asthma, COPD, and asthma-COPD overlap: A comparative study of inflammatory biomarkers and quality of life.Lung India : official organ of Indian Chest Society · 2026Article
- Exploring the Involvement of New Members of the Interleukin Family in Cardiovascular Disease.Current cardiology reviews · 2025Review
- Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2024Review
- IL-33: Friend or foe in transplantation?The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024Review
- Molecular Mechanisms and the Interplay of Important Chronic Obstructive Pulmonary Disease Biomarkers Reveals Novel Therapeutic Targets.ACS omega · 2023Review
- The Role of IL-33/ST2 in COPD and Its Future as an Antibody Therapy.International journal of molecular sciences · 2023Review
- ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses.Frontiers in immunology · 2023Article
- Chronic Lung and Respiratory Conditions Affecting Lungs and Airways.ACS pharmacology & translational science · 2022Article
- Circulating IL-32 and IL-33 levels in patients with asthma and COPD: a retrospective cross-sectional study.Journal of thoracic disease · 2022Article
- Journal Club: Biologics and Potential for Immune Modulation in Chronic Obstructive Lung Disease.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2022Article
- Elastase- and LPS-Exposed Cpa3Frontiers in immunology · 2022Article
- From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease.Biomedicines · 2021Review
- Review
- Endotyping chronic rhinosinusitis based on olfactory cleft mucus biomarkers.The Journal of allergy and clinical immunology · 2021Article
- Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets.Frontiers in physiology · 2021Review
- An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease.Biologics : targets & therapy · 2021Review
- Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time.Frontiers in immunology · 2021Review
- Emerging Leaders in Pharmacology and Translational Science Special Issue Editorial.ACS pharmacology & translational science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-33 has been deorphanized as a member of the IL-1 family and has key roles as an alarmin and cytokine with potent capacity to drive type 2 inflammation. This has led to a plethora of studies surrounding its role in chronic diseases with a type 2 inflammatory component. Here, we review the roles of IL-33 in two chronic respiratory diseases, asthma and chronic obstructive pulmonary disease (COPD). We discuss the hallmark and paradigm-shifting studies that have contributed to our understanding of IL-33 biology. We cover animal studies that have elucidated the mechanisms of IL-33 and assessed the role of anti-IL-33 treatment and immunization against IL-33. We highlight key clinical evidence for the potential of targeting increased IL-33 in respiratory diseases including exacerbations, and we outline current clinical trials using an anti-IL-33 monoclonal antibody in asthma patients. Finally, we discuss some of the challenges that have arisen in IL-33 biology and highlight potential future directions in targeting this cytokine in chronic respiratory diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.